Clinical Trial Detail

NCT ID NCT01454102
Title Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

lung non-small cell carcinoma

Therapies

Bevacizumab

Ipilimumab

Cisplatin

Pemetrexed Disodium

Gemcitabine

Erlotinib

Carboplatin

Paclitaxel

Nivolumab

Age Groups: adult senior

No variant requirements are available.